- Home
- NSSC vs PVLA Comparison
NSSC vs PVLA Comparison
Compare NSSC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSSC
- PVLA
- Stock Information
- Founded
- NSSC 1969
- PVLA 2015
- Country
- NSSC United States
- PVLA United States
- Employees
- NSSC N/A
- PVLA N/A
- Industry
- NSSC Telecommunications Equipment
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- NSSC Telecommunications
- PVLA Health Care
- Exchange
- NSSC Nasdaq
- PVLA Nasdaq
- Market Cap
- NSSC 1.1B
- PVLA 888.0M
- IPO Year
- NSSC N/A
- PVLA N/A
- Fundamental
- Price
- NSSC $39.96
- PVLA $81.40
- Analyst Decision
- NSSC Strong Buy
- PVLA Strong Buy
- Analyst Count
- NSSC 6
- PVLA 13
- Target Price
- NSSC $47.50
- PVLA $99.38
- AVG Volume (30 Days)
- NSSC 297.9K
- PVLA 163.2K
- Earning Date
- NSSC 11-03-2025
- PVLA 11-11-2025
- Dividend Yield
- NSSC 1.39%
- PVLA N/A
- EPS Growth
- NSSC N/A
- PVLA N/A
- EPS
- NSSC 1.23
- PVLA N/A
- Revenue
- NSSC $186,786,000.00
- PVLA N/A
- Revenue This Year
- NSSC $11.30
- PVLA N/A
- Revenue Next Year
- NSSC $8.78
- PVLA N/A
- P/E Ratio
- NSSC $32.71
- PVLA N/A
- Revenue Growth
- NSSC N/A
- PVLA N/A
- 52 Week Low
- NSSC $19.00
- PVLA $11.17
- 52 Week High
- NSSC $48.12
- PVLA $85.30
- Technical
- Relative Strength Index (RSI)
- NSSC 39.11
- PVLA 59.88
- Support Level
- NSSC $39.52
- PVLA $78.99
- Resistance Level
- NSSC $44.46
- PVLA $85.03
- Average True Range (ATR)
- NSSC 2.15
- PVLA 5.58
- MACD
- NSSC -0.43
- PVLA -0.02
- Stochastic Oscillator
- NSSC 25.25
- PVLA 63.39
About NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.